SCHEMBL4881648

SCHEMBL4881648

CC(C)CCN(c1ccc(N2CCOCC2)cc1)c1ncnc2ccc(I)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.40
MAPT P10636 1/20 0.40
AHR P35869 1/20 0.40
HTT P42858 1/20 0.40
PRKDC P78527 10/20 0.39
EGFR P00533 1/20 0.37
CLK1 P49759 1/20 0.36
DYRK1A Q13627 1/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP1A2 P05177 1/20 0.36
ALDH1A1 P00352 2/20 0.36
USP2 O75604 1/20 0.36
PI4KB Q9UBF8 1/20 0.36
PTK2 Q05397 1/20 0.36
TSHR P16473 2/20 0.35
CLK4 Q9HAZ1 2/20 0.35
HIF1A Q16665 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893415 0.83 PRKDC (0.43) MAPK1MAPTPRKDCCLK1DYRK1A
SCHEMBL4890770 0.82 EGFR (0.45) MAPK1MAPTAHRHTTPRKDC
SCHEMBL4892645 0.71 PRKDC (0.45) MAPK1MAPTPRKDCEGFRCLK1
SCHEMBL4007231 0.69 MAPT (0.78) MAPK1MAPTAHRHTTEGFR
SCHEMBL4890763 0.68 MAPT (0.52) MAPK1MAPTAHRHTTPRKDC
SCHEMBL29058418 0.67 CSF1R (0.63) MAPK1HTTEGFRCYP2C19CYP3A4
SCHEMBL4359058 0.67 CYP1A2 (0.56) MAPK1MAPTAHRHTTCLK1
SCHEMBL4891839 0.67 PRKDC (0.45) MAPK1MAPTPRKDCCLK1DYRK1A
SCHEMBL4882141 0.66 MAPT (0.57) MAPK1MAPTAHRHTTPRKDC
SCHEMBL28470356 0.65 PRKDC (0.62) PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents ARROW THERAPEUTICS LIMITED (GB) 2008-12-18 US disclosed
EP-1748991-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS Arrow Therapeutics Limited (GB) 2007-02-07 EP disclosed
WO-2005105761-A1 MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS ARROW THERAPEUTICS LIMITED (GB) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080311076-A1 Morpholinylanilinoquinazoline Derivatives For Use As Antiviral Agents EIF2AK2, MAVS, IRF3 MAPK1 1945/4885MAPT 2064/4885AHR 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.